Cargando…
Possible agent for COVID-19 treatment: Rifampicin
Rifampicin is a promising drug for the treatment of coronavirus disease 2019 based on its antiviral properties and recent in silico studies. In silico studies can serve as a foundation for further studies.
Autores principales: | Aydin, Ozlem Celik, Aydın, Sonay, Barun, Sureyya |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9523331/ https://www.ncbi.nlm.nih.gov/pubmed/36188747 http://dx.doi.org/10.5501/wjv.v11.i5.391 |
Ejemplares similares
-
Role of natural products and intestinal flora on type 2 diabetes mellitus treatment
por: Aydin, Ozlem Celik, et al.
Publicado: (2023) -
Ticagrelor Can Be an Important Agent in the Treatment of Severe COVID-19 Patients with Myocardial Infarction
por: Akşit, Ercan, et al.
Publicado: (2020) -
Imaging of fibroadenoma: Be careful with imaging follow-up
por: Ece, Bunyamin, et al.
Publicado: (2022) -
Utility of cardiac bioenzymes in predicting cardiovascular outcomes in SARS-CoV-2
por: Gulmez, Ali Osman, et al.
Publicado: (2023) -
Commentary on "Primary orbital monophasic synovial sarcoma with calcification: A case report"
por: Tokur, Oguzhan, et al.
Publicado: (2022)